China's Ocumension Therapeutics H1 revenue surges on higher ophthalmic product sales

Ocumension Therapeutics

28/08/2026 15:24

Overview
China ophthalmic pharma firm's half-year revenue rose 44.1% yr/yr to RMB423.7 mln
Adjusted net loss narrowed 46.7% to RMB57.5 mln, reflecting improved operational efficiency
Growth driven by higher ophthalmic product sales and increased royalty income

Outlook
Ocumension expects new product approvals to drive growth momentum in coming periods
Company expects to complete OT-802 clinical trial enrollment for all patients this year
Commercial production of Youshiying expected to be approved in the fourth quarter

Result Drivers
PRODUCT SALES - Co said revenue growth was driven by higher sales of ophthalmic products including Youshiying, Xalatan, Kalacom, Azep and products acquired or in-licensed from Alcon
ROYALTY INCOME - Co said increased sales-based royalty income was largely driven by commercialization of Boyoujing
OPERATIONAL EFFICIENCY - Co attributed narrower adjusted net loss to improved efficiency of operation and revenue growth

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
RMB 423.7 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Ocumension Therapeutics is HK$8.81, about 66.2% above its August 28 closing price of HK$5.30
The stock recently traded at 45 times the next 12-month earnings vs. a P/E of 87 three months ago

Reuters Recommended Reads
Aug 28 - China's Zhaoke Ophthalmology H1 revenue rises
Aug 28 - China's Chaoju Eye Care H1 net profit falls on lower insurance pricing
Aug 26 - China's Jiangsu says it will support pharmaceutical firms' global M&A, licensing

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)